Letter
Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis

This work has been accepted for poster presentation at the 2015 Society for Investigative Dermatology Meeting, Atlanta, May 6-9, 2015.
https://doi.org/10.1016/j.jaad.2015.03.047Get rights and content

First page preview

First page preview
Click to open first page preview

References (5)

There are more references available in the full text version of this article.

Cited by (17)

  • Systemic sclerosis in adults. Part II: management and therapeutics

    2022, Journal of the American Academy of Dermatology
    Citation Excerpt :

    Twice daily application of 25% sodium thiosulfate compounded in zinc oxide for up to 12 months was found to be effective in 19 of 25 patients (15 SSc patients) with CC in a recent case series.188 Additional treatments have been reported in CC associated with dermatomyositis, but not in SSc, are listed in Table II.174,175,189-197 Surgical removal of calcified deposits should be considered only in specific suitable cases that are refractory to pharmacologic therapy and/or due to intractable pain.

  • Calcinosis in dermatomyositis: Origins and possible therapeutic avenues

    2022, Best Practice and Research: Clinical Rheumatology
  • Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis

    2022, Autoimmunity Reviews
    Citation Excerpt :

    Overall, 2782 studies were identified and 175 studies were left for full text review after screening of duplicate, overlap and irrelevant studies. Finally, 29 studies were included in this meta-analysis (n = 576) [1,5–8,27–50]. Baseline patient demographics are detailed in Table 1.

  • Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature

    2020, Journal of the American Academy of Dermatology
    Citation Excerpt :

    In this systematic review, we identified 30 studies (288 patients) focusing on the treatment of calcinosis cutis associated with SSc and dermatomyositis. Table IV summarizes the available treatments for calcinosis cutis with a focus on underlying diseases and levels of evidence.10,20,26-42,47,50-53 Currently, we lack specific guidelines for managing calcinosis cutis in the setting of autoimmune connective tissue disorders.

View all citing articles on Scopus

Funding sources: None.

All authors contributed to the preparation of this manuscript.

Conflicts of interest: Dr Fernandez is a consultant for Amgen and Castle Biosciences, and a consultant and speaker for AbbVie. Drs Galimberti and Li have no conflicts to declare.

IRB statement: This study was approved by the Cleveland Clinic Institutional Review Board.

View full text